Trials / Completed
CompletedNCT04830358
Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults
A Single Center, Randomized, Single-blind, Active Comparator Phase 1 Clinical Trial to Assess the Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- EuBiologics Co.,Ltd · Industry
- Sex
- All
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The safety and immunogenicity of EuPCV15 compared to Prevenar13 are assessed in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EuPCV15 | 15-valent Pneumococcal conjugate vaccine |
| BIOLOGICAL | Prevenar13 | 13-valent Pneumococcal conjugate vaccine |
Timeline
- Start date
- 2020-05-28
- Primary completion
- 2020-08-14
- Completion
- 2021-02-01
- First posted
- 2021-04-05
- Last updated
- 2021-10-07
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04830358. Inclusion in this directory is not an endorsement.